EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee iD, Paola Neri iD, Nizar J Bahlis iD

Blood · 2024

DOI: 10.1182/blood.2023022499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Holly Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Divisions of Hematology and Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Neoplasms, Plasma Cell. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies that engage T cells to target B-cell maturation antigen or G-protein–coupled receptor class C group 5 member D have demonstrated remarkable efficacy in heavily pretreated relapsed or refractory multiple myeloma (MM), leading to the recent accelerated approval of teclistamab, elranatamab, and talquetamab by health agencies. Future challenges, however, remain to define their optimal dosing schedule and duration, sequencing, and integration with established anti-MM therapeutics as well as delineating the biological and clinical mediators of immune escape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificNeoplasms, Plasma CellHumansB-Cell Maturation AntigenReceptors, G-Protein-Coupled

Substanzen

Antibodies, BispecificB-Cell Maturation AntigenReceptors, G-Protein-CoupledGPRC5D protein, human

Autor:innen und Institutionen

  • Department of Medicine, Divisions of Hematology and Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Holly Lee, Paola Neri, Nizar J Bahlis

Zitieren

APA

Lee, H., Neri, P., & Bahlis, N. J. (2024). BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. https://doi.org/10.1182/blood.2023022499

Vancouver

Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024. doi:10.1182/blood.2023022499

BibTeX
@article{Lee2024,
  author = {Lee, Holly and Neri, Paola and Bahlis, Nizar J},
  title = {BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2023022499}
}
Kostenlos starten →